January 10, 2025
Currax Announces Outstanding 2024 Financial and Operational Performance
Read moreJanuary 3, 2025
Currax Introduces First CONTRAVE® TV Ad and “Cravings Don’t Own Me” Campaign, Highlighting Food Cravings Management and Weight Loss
Read moreSeptember 24, 2024
Currax Pharmaceuticals Unveils New Disease Awareness Campaign to “Quiet the Food Noise,” a Key Barrier for Individuals Seeking Weight Loss
Read moreAugust 27, 2024
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
Read moreJuly 24, 2024
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
Read moreJanuary 25, 2024
Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
Read moreOctober 19, 2023
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
Read moreMarch 6, 2023
Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE®
Read moreAugust 30, 2022
One Size Does Not Fit All™: Currax Pharmaceuticals Launches New Campaign to Address Emotional Eating Challenges Faced by Individuals Seeking Weight Loss
Read moreJanuary 7, 2022